Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine if the novel oral agent VT-1161 is safe and effective in treating patients with acute vulvovaginal candidiasis (also referred to as yeast infection). VT-1161 has been designed to inhibit CYP51, an enzyme essential for fungal growth. Inhibition of CYP51 results in the accumulation of chemicals know to be toxic to the fungus. CYP51 is the molecular target of the class of drugs referred to as 'azole antifungals'. All currently approved azole drugs have poor selectivity for CYP51 and this results in many of the side effects associated with the azole antifungals. The safety profile of the class similarly limits use in chronic treatment of non-life-threatening fungal infections. VT-1161 has been design to be safer and more active against the fungal species typically responsible for vaginal yeast infections (i.e. vulvovaginal candidiasis).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01891331
Study type Interventional
Source Viamet
Contact
Status Completed
Phase Phase 2
Start date August 2013
Completion date December 2014

See also
  Status Clinical Trial Phase
Completed NCT02971007 - Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Phase 2
Completed NCT02251093 - Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Phase 3
Completed NCT01293643 - A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Phase 3
Not yet recruiting NCT04626258 - Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis Phase 4
Completed NCT02733432 - RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Phase 2
Completed NCT02248506 - Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Phase 4
Completed NCT02730494 - Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Phase 1
Completed NCT02180828 - Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Phase 4
Recruiting NCT04930107 - Vulvovaginal Candidiasis in Canadian Females Early Phase 1
Withdrawn NCT03167957 - Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Phase 2
Recruiting NCT05367089 - The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms Phase 3
Terminated NCT02859493 - Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis N/A
Completed NCT02888197 - Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization N/A
Completed NCT03975569 - Study of the Vaginal Microbiota and the Potential of a Vaginal Probiotic Cream in Vaginal Candidosis N/A
Recruiting NCT05059145 - A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis Phase 2
Recruiting NCT03075046 - Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial N/A